These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35764491)

  • 41. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
    Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A
    Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
    Luo J; Gagne JJ; Landon J; Avorn J; Kesselheim AS
    Eur J Cancer; 2017 Jan; 70():22-33. PubMed ID: 27866096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
    Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
    Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
    van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
    Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
    Ramasamy K; Dhanasiri S; Thom H; Buchanan V; Robinson S; D'Souza VK; Weisel K
    Leuk Lymphoma; 2020 Mar; 61(3):668-679. PubMed ID: 31709875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New treatments for myeloma.
    Azaïs I; Brault R; Debiais F
    Joint Bone Spine; 2010 Jan; 77(1):20-6. PubMed ID: 20031467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
    Chang HJ; Lee JH; Do YR; Bae SH; Lee JL; Nam SH; Yoon SS; Bang SM
    Korean J Intern Med; 2011 Dec; 26(4):403-9. PubMed ID: 22205840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat.
    Chari A; Bhor M; Eldjerou L; Gilligan AM; Urniasz A; Globe D; Stetsovsky D; Varker H; Davis B; Bonafede M; Talcott J
    Future Oncol; 2018 Sep; 14(21):2149-2160. PubMed ID: 29846095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.
    Fatoye F; Smith P; Gebrye T; Yeowell G
    BMJ Open; 2019 Apr; 9(4):e027049. PubMed ID: 30987990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
    Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
    Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime].
    Hardi A; Varga G; Nagy Z; Kosztolányi S; Váróczy L; Plander M; Schneider T; Demeter J; Alizadeh H; Illés Á; Masszi T; Mikala G
    Orv Hetil; 2021 Sep; 162(36):1451-1458. PubMed ID: 34482291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical updates and nursing considerations for patients with multiple myeloma.
    Faiman B
    Clin J Oncol Nurs; 2007 Dec; 11(6):831-40. PubMed ID: 18063542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
    CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
    Favier-Archinard C; Leguelinel-Blache G; Dubois F; Le Gall T; Bourquard P; Passemard N; Tora S; Rey A; Rossi M; Chevallier T; Cousin C; Favier M
    Bull Cancer; 2018 May; 105(5):475-485. PubMed ID: 29573809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
    Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
    J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
    Nardone B; Wu S; Garden BC; West DP; Reich LM; Lacouture ME
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):424-9. PubMed ID: 23769670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.